Skip to main content
CHRS logo

Coherus Oncology, Inc.

CHRSNASDAQHealthcareBiotechnology

$1.01Today:- (-)1Y −37.13%

As of Oct 26, 2026 close

Market cap
$156.37M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.94$2.62
Volume (live)
-
Avg. volume (3M)
1.53M

Coherus Oncology, Inc. (CHRS) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Coherus Oncology, Inc. stock.

Analyst Consensus Rating

Investment consensus from 4 professional research analysts

Consensus Rating

Buy
Based on 4 unique analysts
Low Confidence∞:1 Buy/Sell

Average Price Target

$7.75
+667.33% upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest CHRS Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Douglas Tsao
HC Wainwright
BuyReiterates
$7.00
Jason McCarthy
Maxim
BuyMaintains
$4.00
Paul Jeng
Guggenheim
BuyMaintains
$12.00 → $10.00
Jay Olson
Oppenheimer
BuyMaintains
$10.00

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Sep 21, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for CHRS?

The analyst consensus rating for CHRS is Buy, based on the latest ratings from 4 analysts over the last 90 days.

What is the average price target for CHRS?

The average 12-month price target for CHRS is $7.75, representing an upside of 667.3% from the Oct 26, 2026 close of $1.01.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.